Novartis (NVS) announced positive data on breast cancer drug Kisqali (ribociclib) from the late-stage study, NATALEE. This late-breaking data from this four-year post-hoc analysis was presented at the European Society for Medical Oncology ("ESMO") Congress 2024. Data showed that Kisqali, when added to endocrine therapy (ET), reduced the risk of disease recurrence by 28.5% in a broad population of patients with early breast cancer (EBC). Shares of NVS rose 1% on the news. Year to date, shares of Novartis hav ...

Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhibitor adjuvant therapy1,2 Kisqali® (ribociclib) significantly reduced the risk of recurrence by 25% vs. endocrine therapy (ET) alone; consistent benefit and a well-tolerated safety profile seen across all subgroups in pivotal Phase III NATALEE trial, including patients with node-negative disease3-6 Late-breakin ...

Key Takeaways Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease. The drug maker reported Kisqali along with endocrine therapy (ET) reduced the risk of recurrence in the test group by nearly 30% compared to ET alone. Novartis expects the FDA to decide on approval of the treatment this quarter. American depositary receipts (ADRs) of Novartis (NVS) gained Monday as new research showed the company's breast cancer treatment, Kisqali, produced longer ...

Invasive disease-free survival benefit continued to increase after completion of the three-year treatment period across all patient subgroups, including those with node-negative disease1 Results remain consistent across secondary endpoints, including distant disease-free survival, with a trend for improved overall survival*1 Safety is in line with previously reported results with generally low-grade symptomatic adverse events, reinforcing well-tolerated profile1 People diagnosed with stage II or III HR+/HER ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Considering buying NVS stock? Here's what analysts think: Novartis AG has a consensus price target of $120.25 based on the ratings of 10 analysts. The high is $130 issued by B of A Securities on September 11, 2024. The low is $114 issued by Morgan Stanley on January 23, 2024. The 3 most-recent analyst ratings were releas ...

Swiss pharma giant Novartis (NVS) has agreed to license a novel capsid generated from Voyager Therapeutics, Inc's (VYGR) capsid platform for use in a gene therapy program. Per Voyager, NVS will use this novel capsid for use in a gene therapy program against an undisclosed rare neurologic disease target. Shares of Novartis have risen 15.4% year to date compared with the industry's growth of 27%. Image Source: Zacks Investment Research Novartis' Deal With VYGR VYGR granted this capsid license to NVS per the t ...

Goldman Sachs has downgraded Novartis AG NVS, citing "limited value driving innovation catalysts in the near term." The analyst writes that continued earnings momentum has led to increases in revenue and profit forecasts for fiscal years 2024 and 2025 since the beginning of the year, thanks to upgraded fiscal year 2024 guidance provided in the first and second quarters of 2024. Also Read: Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs. Moreover, from a valuation s ...

Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Novartis (NVS) or Eli Lilly (LLY) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores wor ...

Investors might want to bet on Novartis (NVS) , as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. Since a changi ...

Phase III V-MONO study met its primary endpoints, demonstrating superiority of Leqvio (inclisiran) monotherapy vs both placebo and ezetimibe in LDL-C reduction1 Results add to growing body of evidence for Leqvio across the ASCVD continuum Data will be shared with regulatory agencies and presented at an upcoming medical meeting V-MONO is part of the 60,000-patient VictORION clinical trial program assessing Leqvio for primary and secondary ASCVD prevention Basel, August 28, 2024 – Novartis announced today pos ...